NovaBay Pharmaceuticals Net Worth

NovaBay Pharmaceuticals Net Worth Breakdown

  NBY
The net worth of NovaBay Pharmaceuticals is the difference between its total assets and liabilities. NovaBay Pharmaceuticals' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of NovaBay Pharmaceuticals' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. NovaBay Pharmaceuticals' net worth can be used as a measure of its financial health and stability which can help investors to decide if NovaBay Pharmaceuticals is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in NovaBay Pharmaceuticals stock.

NovaBay Pharmaceuticals Net Worth Analysis

NovaBay Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including NovaBay Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of NovaBay Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform NovaBay Pharmaceuticals' net worth analysis. One common approach is to calculate NovaBay Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares NovaBay Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing NovaBay Pharmaceuticals' net worth. This approach calculates the present value of NovaBay Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of NovaBay Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate NovaBay Pharmaceuticals' net worth. This involves comparing NovaBay Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into NovaBay Pharmaceuticals' net worth relative to its peers.
To determine if NovaBay Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding NovaBay Pharmaceuticals' net worth research are outlined below:
NovaBay Pharmaceuticals has some characteristics of a very speculative penny stock
NovaBay Pharmaceuticals had very high historical volatility over the last 90 days
NovaBay Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the last year's revenue of 14.73 M. Reported Net Loss for the year was (9.64 M) with profit before taxes, overhead, and interest of 7.87 M.
NovaBay Pharmaceuticals has about 5.36 M in cash with (4.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07.
NovaBay Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in NovaBay Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to NovaBay Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Follow NovaBay Pharmaceuticals' market capitalization trends

The company currently falls under 'Nano-Cap' category with a total capitalization of 2.96 M.

Project NovaBay Pharmaceuticals' profitablity

The company has Net Profit Margin of (0.73) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.43) %, which entails that for every $100 of revenue, it lost $0.43.
When accessing NovaBay Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures NovaBay Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of NovaBay Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in NovaBay Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NovaBay Pharmaceuticals. Check NovaBay Pharmaceuticals' Beneish M Score to see the likelihood of NovaBay Pharmaceuticals' management manipulating its earnings.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NovaBay Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on NovaBay Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NovaBay Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NovaBay Pharmaceuticals time-series forecasting models is one of many NovaBay Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary NovaBay Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

NovaBay Pharmaceuticals Earnings per Share Projection vs Actual

NovaBay Pharmaceuticals Corporate Executives

Elected by the shareholders, the NovaBay Pharmaceuticals' board of directors comprises two types of representatives: NovaBay Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NovaBay. The board's role is to monitor NovaBay Pharmaceuticals' management team and ensure that shareholders' interests are well served. NovaBay Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NovaBay Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew JonesChief Financial Officer, TreasurerProfile

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.